Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · IEX Real-Time Price · USD
45.12
+0.35 (0.78%)
At close: Jul 19, 2024, 4:00 PM
45.00
-0.12 (-0.27%)
Pre-market: Jul 22, 2024, 7:43 AM EDT
Avidity Biosciences Revenue
Avidity Biosciences had revenue of $10.87M in the twelve months ending March 31, 2024, with 12.50% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $3.54M with 58.67% year-over-year growth. In the year 2023, Avidity Biosciences had annual revenue of $9.56M with 3.64% growth.
Revenue (ttm)
$10.87M
Revenue Growth
+12.50%
P/S Ratio
396.98
Revenue / Employee
$42,964
Employees
253
Market Cap
4.32B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
| Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
| Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
| Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
| Dec 31, 2019 | 2.32M | 1.94M | 511.87% |
| Dec 31, 2018 | 379.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alkermes | 1.73B |
| RadNet | 1.66B |
| Integer Holdings | 1.63B |
| Haemonetics | 1.31B |
| Inspire Medical Systems | 660.91M |
| Apellis Pharmaceuticals | 524.07M |
| TransMedics Group | 296.92M |
| CRISPR Therapeutics AG | 271.71M |
RNA News
- 27 days ago - Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors - Business Wire
- 4 weeks ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day - PRNewsWire
- 4 weeks ago - Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 5 weeks ago - Avidity Biosciences to Participate in Upcoming Investor Conference - PRNewsWire
- 5 weeks ago - Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock - PRNewsWire
- 5 weeks ago - Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock - PRNewsWire
- 5 weeks ago - Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday - Benzinga